Drug intelligence / Profile preview

VS-241

Development stage: Preclinical
Lead developer: Vasa Therapeutics
Modality: Peptides
Administration: Parenteral

Overview

VS-241 is a Vasa Therapeutics investigational long-acting apelin therapeutic being developed for age-related cardiovascular and neuromuscular disorders. It is reported to act as an agonist of the apelin receptor, with development focused on sarcopenia and peripheral artery disease. Public company-related reporting indicated that clinical testing was planned for 2026; no INN, marketed brand name, formulation, route of administration, or manufacturer has been publicly confirmed.

Targets

APLNR (Apelin receptor)

Beyond the preview

Go deeper on VS-241.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VS-241.

Explore the full profile